[Federal Register: May 23, 2002 (Volume 67, Number 100)]
[Notices]
[Page 36206]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23my02-84]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Treatment of Central
Nervous System Disorders With a Combination of Dopaminergic and
Adrenergic Antagonists
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in:
U.S. Patent Numbers 5,492,907, filed December 9, 1992, issued February
20, 1996 and 5,663,167, filed June 7, 1995, issued September 2, 1997,
both entitled ``Antipsychotic composition and method of treatment'' to
Potomac Pharma, Inc., having a place of business in Cabin John,
Maryland. The patent rights in these inventions have been assigned to
the United States of America.
The contemplated exclusive license may be limited to the use of
methods disclosed and claimed in the invention and treatment of human
central nervous system disorders.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before July
22, 2002, will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Norbert J. Pontzer, J.D., Ph.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; telephone: (301) 496-7736, ext. 284; facsimile: (301)
402-0220, e-mail: np59n@ott.nih.gov. A signed Confidential Disclosure
Agreement will be required to receive copies of the patent application.
SUPPLEMENTARY INFORMATION: A significant number of patients suffering
from schizophrenia prove resistant to treatment with typical
neuroleptics. Scientists at the NIH discovered that the administration
of an alpha2-adrenergic receptor antagonist unexpectedly
enhances the therapeutic effect of typical antipsychotic neuroleptics.
The present invention provides an improved treatment for patients
suffering from serious psychotic mental illness who have proven
resistant to treatments with known typical antipsychotic neuroleptics
alone.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 13, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 02-13017 Filed 5-22-02; 8:45 am]
BILLING CODE 4140-01-P